Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 196

Sort by

Sort Order Select

Journal Articles

B- and T-cell clonality using peripheral blood cell-free RNA (cfRNA) in liquid biopsy

Adam Albitar, Alfonso Lam, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David Vesole, Harsh Parmar, Andrew Pecora, Andrew Ip, Andre Goy, David Siegel, Maher Albitar

Blood (2025) 146 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2025-1754

Published: 2025

Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Blood (2025) 146 (Supplement 1): 884.

https://doi.org/10.1182/blood-2025-884

Published: 2025

Journal Articles

Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy

Blood (2025) 146 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2025-1799

Published: 2025

Journal Articles

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

Maher Albitar, Hong Zhang, Gustavo Rivero, David Swoboda, Sally Agersborg, Adam Albitar, Ahmad Charifa, Andrew Ip, Andre Goy, Andrew Pecora, David Siegel, Kelly West Fitzpatrick, Katherine Linder, Jamie Koprivnikar, James McCloskey

Blood (2025) 146 (Supplement 1): 5251.

https://doi.org/10.1182/blood-2025-5251

Published: 2025

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 3711.

https://doi.org/10.1182/blood-2025-3711

Published: 2025

Journal Articles

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Blood (2025) 146 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2025-2710

Published: 2025

Journal Articles

Bone marrow microenvironment overlap between vexas and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence

Maher Albitar, Sally Agersborg, Hong Zhang, Adam Albitar, Ahmad Charifa, Andrew Pecora, David Siegel, Andre Goy, Jamie Koprivnikar, James McCloskey, Katherine Linder

Blood (2025) 146 (Supplement 1): 5611.

https://doi.org/10.1182/blood-2025-5611

Published: 2025

Journal Articles

Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors

Blood (2025) 146 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2025-3471

Published: 2025

Journal Articles

Developing artificial intelligence-based transcriptomic signature for the diagnosis of dark zone lymphoma in patients without MYC gene rearrangement

Andrew Ip, Maher Albitar, Hong Zhang, Sally Agersborg, Adam Albitar, Ahmad Charifa, Andrew Pecora, David Siegel, Lori Leslie, Andre Goy, Tatyana Feldman

Blood (2025) 146 (Supplement 1): 3525.

https://doi.org/10.1182/blood-2025-3525

Published: 2025

Journal Articles

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3

Blood blood.2025029734.

https://doi.org/10.1182/blood.2025029734

Published: 2025

Includes: Supplemental data

Journal Articles

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Blood (2024) 144 (Supplement 1): 4388.

https://doi.org/10.1182/blood-2024-198018

Published: 2024

Journal Articles

Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David H. Vesole, Harsh Parmar, Andrew L Pecora, Andrew Ip, Andre Goy, David S. Siegel

Blood (2024) 144 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2024-203774

Published: 2024

Journal Articles

Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Andrew L Pecora, Lori A. Leslie, Tatyana Feldman, Andrew Ip, Andre Goy

Blood (2024) 144 (Supplement 1): 4367.

https://doi.org/10.1182/blood-2024-203834

Published: 2024

Journal Articles

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Maher Albitar, Sally Agersborg, Ahmad Charifa, Hong Zhang, Andrew Ip, Katherine Linder, Andrew L Pecora, Jamie Koprivnikar, Andre Goy, James McCloskey

Blood (2024) 144 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2024-203870

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David H. Vesole, Harsh Parmar, Andrew L Pecora, Andrew Ip, Andre Goy, David S. Siegel

Blood (2024) 144 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2024-201810

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control

Mimi Chen, Wenbin Mo, Gennaro Clando, Yuanyuan Tian, Ciril Abraham, Qingrong Huang, Ying WANG, Morgan Chaunzwa, Yan Zhou, Andrew Ip, Andre Goy, Jaroslav Jelinek, Jozef Madzo, Jean-Pierre Issa, Yi Zhang

Blood (2024) 144 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2024-207438

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

B- and T-cell clonality using peripheral blood cell-free RNA (cfRNA) in liquid biopsy

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Bone marrow microenvironment overlap between vexas and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence

Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors

Developing artificial intelligence-based transcriptomic signature for the diagnosis of dark zone lymphoma in patients without MYC gene rearrangement

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)

Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only